NEWSPAPER PUBLICATION OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beryl Drugs Ltd has published its audited financial results for FY2026 (year ended 31 March 2026). Total revenue declined to Rs 1931.02 lakhs from Rs 2255.48 lakhs in FY2025, representing a 14.4% drop in annual revenue. Net profit after tax fell to Rs 42.48 lakhs from Rs 56.75 lakhs in the previous year. Total comprehensive income also declined significantly to Rs 40.67 lakhs from Rs 85.70 lakhs. Earnings per share declined from Rs 1.12 to Rs 0.84. However, reserves increased marginally from Rs 438.71 lakhs to Rs 479.38 lakhs. For the standalone Q4 FY26 quarter, revenue was Rs 546.74 lakhs with net profit after tax of Rs 56.25 lakhs.
The company reported a decline in both revenue and profitability year-on-year, which may concern shareholders. The EPS decline from Rs 1.12 to Rs 0.84 reflects reduced earnings. The increase in reserves shows some retained earnings accumulation despite lower profits.